[go: up one dir, main page]

NI201500059A - Inhibidores de la tirosina-quinasa de bruton - Google Patents

Inhibidores de la tirosina-quinasa de bruton

Info

Publication number
NI201500059A
NI201500059A NI201500059A NI201500059A NI201500059A NI 201500059 A NI201500059 A NI 201500059A NI 201500059 A NI201500059 A NI 201500059A NI 201500059 A NI201500059 A NI 201500059A NI 201500059 A NI201500059 A NI 201500059A
Authority
NI
Nicaragua
Prior art keywords
tyrosine kinase
compounds
conditions
kinase inhibitors
bruton tyrosine
Prior art date
Application number
NI201500059A
Other languages
English (en)
Inventor
Robert Springer John
Devadas Balekudru
James Garland Danny
Lanahan Grapperhaus Margaret
Han Seungil
Landis Hockerman Susan
Owen Hughes Robert
Saiah Eddine
Edward Schnute Mark
Raj Selness Shaun
Patrick Walker Daniel
Wan Zhao-Kui
Xing Li
Wolfgang Zapf Christoph
Ann Schmidt Michelle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201500059(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NI201500059A publication Critical patent/NI201500059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente compuestos que forman enlaces covalentes con tirosina quinasa de Bruton (BTK). Se describen los métodos para la preparación de los compuestos. Se describen también composiciones farmacéuticas que incluyen los compuestos. Se describen los métodos de uso de los inhibidores de BTK, sólos o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, que incluye linfoma y enfermedades o condiciones inflamatorias. ( Fórmula I).
NI201500059A 2012-11-02 2015-04-30 Inhibidores de la tirosina-quinasa de bruton NI201500059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04

Publications (1)

Publication Number Publication Date
NI201500059A true NI201500059A (es) 2015-06-05

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500059A NI201500059A (es) 2012-11-02 2015-04-30 Inhibidores de la tirosina-quinasa de bruton

Country Status (27)

Country Link
US (4) US20150291554A1 (es)
EP (1) EP2914586B1 (es)
JP (1) JP6178861B2 (es)
KR (1) KR101668574B1 (es)
CN (1) CN105008344B (es)
AP (1) AP2015008381A0 (es)
AU (1) AU2013340345B2 (es)
BR (1) BR112015009624A2 (es)
CA (1) CA2888960C (es)
CL (1) CL2015001168A1 (es)
CO (1) CO7350624A2 (es)
CR (1) CR20150228A (es)
DO (1) DOP2015000100A (es)
EA (1) EA201500393A1 (es)
ES (1) ES2625944T3 (es)
GE (1) GEP201606597B (es)
HK (1) HK1211293A1 (es)
IL (1) IL238571A0 (es)
MD (1) MD20150035A2 (es)
MX (1) MX2015005422A (es)
NI (1) NI201500059A (es)
PE (1) PE20151070A1 (es)
PH (1) PH12015500940A1 (es)
SG (1) SG11201502893WA (es)
TN (1) TN2015000168A1 (es)
TW (1) TWI518080B (es)
WO (1) WO2014068527A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001802A (es) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
HK1211942A1 (en) 2012-09-10 2016-06-03 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014151620A1 (en) 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
JP6495886B2 (ja) 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としての複素環式芳香族化合物
JP6777398B2 (ja) * 2013-03-15 2020-10-28 ヤンセン ファーマシューティカ エヌ．ベー． 薬剤を調製するための方法と中間体
CN113413537A (zh) 2013-08-19 2021-09-21 塔里斯生物医药公司 多单元药物递送装置和方法
PL3052476T3 (pl) * 2013-09-30 2021-01-11 Guangzhou Innocare Pharma Tech Co., Ltd. Podstawione nikotynoimidowe inhibitory btk oraz sposób ich wytwarzania i zastosowanie w leczeniu raka, stanu zapalnego i chorób automunnologicznych
WO2015116485A1 (en) 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
MX372673B (es) 2014-02-21 2020-03-25 Principia Biopharma Inc Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN106687446B (zh) * 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
EP3377484B1 (en) * 2015-11-17 2023-09-06 Merck Patent GmbH Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
JP6976947B2 (ja) 2015-12-16 2021-12-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫疾患の処置に有用なビピラゾリル誘導体
CN114591242B (zh) 2015-12-16 2025-01-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
JP6916185B2 (ja) 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのイソキノロン類
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
KR102404759B1 (ko) * 2016-05-16 2022-05-31 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. Ｂｔｋ 억제제로서의 5-아미노피라졸 카르복사미드 유도체 및 그것의 제조 방법 및 제약학적 조성물
EA201892836A1 (ru) 2016-06-29 2019-07-31 Принсипиа Биофарма Инк. Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
AU2018364183B2 (en) * 2017-11-10 2020-10-15 Sinomab Bioscience Limited Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
WO2019091441A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
ES2945834T3 (es) 2018-10-05 2023-07-07 Forma Therapeutics Inc Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
CA3131894A1 (en) * 2019-03-14 2020-09-17 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
JP7774448B2 (ja) 2019-05-21 2025-11-21 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
MX2022004427A (es) 2019-10-14 2022-07-12 Principia Biopharma Inc Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022009009A (es) 2020-01-22 2022-08-15 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
AU2021342161A1 (en) * 2020-09-11 2023-05-25 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115611810B (zh) * 2021-07-16 2025-03-04 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
CN116554102B (zh) * 2022-01-28 2025-10-03 深圳海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法和应用
US20250145599A1 (en) * 2022-02-04 2025-05-08 Retune Pharma Inc. Certain chemical entities, compositions, and methods
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途
CN120569391A (zh) * 2023-01-19 2025-08-29 北京普祺医药科技股份有限公司 一种吡唑并环类化合物、药物组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds
US7589214B2 (en) * 2006-04-11 2009-09-15 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AU2008276521B2 (en) * 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
EP3311818A3 (en) * 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
EP3461824B1 (en) * 2009-09-04 2021-08-25 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
MX2015001802A (es) * 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10105632B2 (en) 2014-04-09 2018-10-23 Donaldson Company, Inc. Self-supporting folded sheet material, filter elements, and methods
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
CN105008344A (zh) 2015-10-28
GEP201606597B (en) 2017-01-10
BR112015009624A2 (pt) 2017-11-14
TW201431851A (zh) 2014-08-16
TWI518080B (zh) 2016-01-21
US10815213B2 (en) 2020-10-27
ES2625944T3 (es) 2017-07-21
KR20150075114A (ko) 2015-07-02
EP2914586A1 (en) 2015-09-09
EA201500393A1 (ru) 2016-05-31
JP2015535277A (ja) 2015-12-10
PE20151070A1 (es) 2015-08-01
US10266513B2 (en) 2019-04-23
CL2015001168A1 (es) 2015-07-10
WO2014068527A1 (en) 2014-05-08
CR20150228A (es) 2015-09-14
SG11201502893WA (en) 2015-05-28
TN2015000168A1 (fr) 2016-10-03
EP2914586B1 (en) 2017-04-05
US20170283393A1 (en) 2017-10-05
JP6178861B2 (ja) 2017-08-09
AU2013340345A1 (en) 2015-04-30
PH12015500940A1 (en) 2015-06-29
CO7350624A2 (es) 2015-08-10
AU2013340345B2 (en) 2016-10-27
CA2888960A1 (en) 2014-05-08
CN105008344B (zh) 2017-07-25
HK1211293A1 (en) 2016-05-20
DOP2015000100A (es) 2015-12-31
CA2888960C (en) 2017-08-15
IL238571A0 (en) 2015-06-30
US20210002251A1 (en) 2021-01-07
AP2015008381A0 (en) 2015-04-30
US20190202798A1 (en) 2019-07-04
MX2015005422A (es) 2015-08-05
MD20150035A2 (ro) 2015-10-31
KR101668574B1 (ko) 2016-10-24
US20150291554A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
CY1120866T1 (el) Παρεμποδιστες dna-pk
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
NI201500140A (es) Compuestos y composiciones terapéuticos
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
UY33616A (es) Compuestos con estructura de imidazotriazinona
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
AR098781A1 (es) Compuestos peptidomiméticos y conjugados anticuerpos-droga de los mismos
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa